
Margin Upgrade Credible, But This Quarter's Not Repeatable
margin expansion · one-off inflated · CDMO growth

margin expansion · one-off inflated · CDMO growth

spin-off · customer concentration · unprofitable

spin-off transition · distribution rebuild · brand relicensing

skincare · going concern · margin turnaround

pharma api · margin compression · revenue deceleration

margin compression · cash flow risk · FDA observations

revenue growth · margin pressure · FDA observations

pharmaceuticals · electronics · consolidated turnaround

raw materials inflation · FDA remediation · crop protection loss

revenue growth 36% · PAT loss -6 Cr · FDA remediation headwind
pharmaceuticals · margin expansion · inorganic growth

margin compression · guidance cut · MCC expansion

MCC expansion delay · PAT compression · capacity utilization

CDMO · volume growth · Baddi capex

CDMO volume growth · EBITDA expansion · Baddi capex ramp

clinical stage biopharma · phase 3 trials · alzheimers trial

pharmaceuticals · cdmo · biologics

bulk drugs chemicals · vitamin b12 · overseas subsidiary losses

pharma intermediates · contrast media · qip capital raise

pharmaceuticals manufacturing · margin expansion · profit outpaces revenue

animal health · vaccines · poultry healthcare

Xanthine guidance cut · CDMO growth · working capital strain

Xanthine price normalization · CDMO 40-50% growth · Capex ₹350-400 Cr

R&D pipeline slowdown · biologics ramp · preclinical CAGR 30%

pharma exports · margin compression · revenue growth

pharmaceuticals · margin expansion · us generics

pharma generics · margin expansion · europe expansion

diagnostics · margin expansion · revenue growth

active pharmaceutical ingredients · api manufacturing · margin expansion

biosimilars · margin compression · segment results